Kathleen P. Bloch Sells 32,400 Shares of Cytosorbents Corp (CTSO) Stock
Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 32,400 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $7.30, for a total transaction of $236,520.00. Following the transaction, the chief financial officer now owns 248,638 shares of the company’s stock, valued at $1,815,057.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down $0.05 during trading hours on Wednesday, reaching $7.35. 116,110 shares of the company traded hands, compared to its average volume of 139,094. Cytosorbents Corp has a twelve month low of $3.30 and a twelve month high of $7.55. The firm has a market cap of $210.88, a P/E ratio of -19.34 and a beta of -0.54. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17.
CTSO has been the subject of a number of recent research reports. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Monday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Cytosorbents in a research note on Tuesday, November 21st. B. Riley reiterated a “buy” rating and issued a $11.25 target price on shares of Cytosorbents in a research note on Friday, November 10th. Finally, ValuEngine upgraded shares of Cytosorbents from a “sell” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.60.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.